Pertagen (recombinant aP) / BioNet Asia - LARVOL DELTA

Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Pregnant Women (clinicaltrials.gov) - P=N/A | N=2700 | Recruiting | Sponsor: BioNet-Asia Co., Ltd.

New trial • Cough • Infectious Disease • Pertussis • Respiratory Diseases

10-year Follow-up After a Single Dose Acellular Pertussis Vaccination (clinicaltrials.gov) - P4 | N=90 | Not yet recruiting | Sponsor: Mahidol University

New P4 trial • Infectious Disease • Pertussis • Respiratory Diseases

BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) (Businesswire) - "BioNet Europe...has announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine (RPV)."

EMA filing • Infectious Disease • Pertussis

Pertagen2x: Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines (clinicaltrials.gov) - P2/3; N=100; Recruiting; Sponsor: University Hospital, Geneva

Clinical • New P2/3 trial • Infectious Disease • Pertussis • Respiratory Diseases

5-year Follow-up After a Single Dose Acellular Pertussis Vaccination (clinicaltrials.gov) - P=N/A; N=159; Completed; Sponsor: Mahidol University; Enrolling by invitation ➔ Completed

Trial completion • Infectious Disease • Pertussis • Respiratory Diseases

[VIRTUAL] RECOMBINANT ACELLULAR PERTUSSIS VACCINATION DURING PREGNANCY INDUCES HIGH CORD BLOOD PERTUSSIS ANTIBODIES (ESPID 2021) - "Clinical Trial Registration: Thai Clinical Trial Registry TCTR20200528006 Background: Two genetically inactivated acellular pertussis vaccines, a recombinant pertussis-only vaccine (Pertagen®, aPgen) and the combined formulation containing aPgen, tetanus and reduced diphtheria toxoids (Boostagen®, TdaPgen) are licensed in Thailand for booster pertussis immunisation in individuals aged 11 years and older, including pregnant women. Maternal vaccination with genetically-detoxified Pertussis Toxin (PTgen) containing recombinant pertussis vaccines may provide long-lasting protection against severe pertussis in young infants. In addition, the availability of monovalent aPgen vaccine provides an alternative to Tdap vaccines for maternal pertussis immunization when Td vaccination in pregnant women is not needed."

Infectious Disease • Pertussis • Respiratory Diseases • Tetanus